等待開盤 10-23 09:30:00 美东时间
-0.450
-3.86%
今日重点评级关注:摩根大通:维持Cogent Biosciences"超配"评级,目标价从30美元升至44美元;Piper Sandler:维持Vital Energy"中性"评级,目标价从16美元升至30美元
10-22 10:10
Cormedix (NASDAQ:CRMD) underwent analysis by 4 analysts in the last quarter, re...
10-22 06:01
今日重点评级关注:Maxim Group:维持Rani Therapeutics Hldgs"买入"评级,目标价从5美元升至10美元;韦德布什:维持Corbus Pharmaceuticals"跑赢大市"评级,目标价从31美元升至38美元
10-21 18:13
D. Boral Capital analyst Jason Kolbert upgrades Cormedix (NASDAQ:CRMD) from Hold to Buy and announces $14 price target.
10-20 21:33
REPL: 81% | The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivolumab For Advanced Melanoma, PDUFA Date Is April 10, 2026 DVLT: 20% | Datavault AI
10-20 19:36
CorMedix shares are trading higher after the company raised its 2025 pro forma ...
10-20 19:33
CorMedix Inc. reported Q3 2025 unaudited pro forma net revenue of over $125 million, including $85 million for DefenCath, and raised its FY 2025 pro forma net revenue guidance to at least $375 million, up from $325-$350 million. The company expects Q3 2025 adjusted EBITDA of at least $70 million and forecasts $30 million in operating synergies by year-end 2025. CorMedix has completed enrollment in the Phase III ReSPECT study for Rezzayo, with cli...
10-20 11:30
CorMedix Inc. announced the completion of enrollment for its Phase III ReSPECT trial evaluating the efficacy of REZZAYO® (rezafungin) in preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. Sponsored by Mundipharma, the trial aims to assess once-weekly rezafungin against a standard antimicrobial regimen. Topline results are expected in Q2 2026. REZZAYO is approved in the U.S. for treating candidem...
09-29 12:30
今日重点评级关注:D. Boral Capital:维持Veritone"买入"评级,目标价从6美元升至26美元;Guggenheim:维持Dianthus Therapeutics"买入"评级,目标价从92美元升至100美元
09-10 18:01
During the last three months, 6 analysts shared their evaluations of Cormedix (...
09-10 02:01